Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zidovudine and Interferon alfa-2a in AIDS-Associated Kaposi's Sarcoma
NCT00000687Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of interferon alfa-2a and zidovudine in Kaposi's sarcoma (KS), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Rate of Tumor Response up to 52 weeks and Adverse Events up to 52 weeks. Status: completed.
02
Drugs
interferon alfa-2azidovudine
03
Conditions
Kaposi's sarcoma (KS)
Beyond the preview
Go deeper on NCT00000687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000687.